Considerations for the Use of Phage Therapy in Clinical Practice

Gina A. Suh, Thomas P. Lodise, Pranita D. Tamma, Jane M. Knisely, Jose Alexander, Saima Aslam, Karen D. Barton, Erica Bizzell, Katherine M.C. Totten, Joseph L. Campbell, Benjamin K. Chan, Scott A. Cunningham, Katherine E. Goodman, Kerryl E. Greenwood-Quaintance, Anthony D. Harris, Shayla Hesse, Anthony Maresso, Veronique Nussenblatt, David Pride, Michael J. RybakZoe Sund, David Van Duin, Daria Van Tyne, Robin Patel

Research output: Contribution to journalArticlepeer-review

Abstract

Increasing antimicrobial resistance and medical device-related infections have led to a renewed interest in phage therapy as an alternative or adjunct to conventional antimicrobials. Expanded access and compassionate use cases have risen exponentially but have varied widely in approach, methodology, and clinical situations in which phage therapy might be considered. Large gaps in knowledge contribute to heterogeneity in approach and lack of consensus in many important clinical areas. The Antibacterial Resistance Leadership Group (ARLG) has convened a panel of experts in phage therapy, clinical microbiology, infectious diseases, and pharmacology, who worked with regulatory experts and a funding agency to identify questions based on a clinical framework and divided them into three themes: potential clinical situations in which phage therapy might be considered, laboratory testing, and pharmacokinetic considerations. Suggestions are provided as answers to a series of questions intended to inform clinicians considering experimental phage therapy for patients in their clinical practices.

Original languageEnglish (US)
Article numbere02071-21
JournalAntimicrobial Agents and Chemotherapy
Volume66
Issue number3
DOIs
StatePublished - Mar 2022

Keywords

  • biofilms
  • phages
  • Pseudomonas aeruginosa
  • Staphylococcus aureus

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Considerations for the Use of Phage Therapy in Clinical Practice'. Together they form a unique fingerprint.

Cite this